Rémy Boussageon

Rémy Boussageon

Auto-generated profile, based on publicly available information

Rémy Boussageon

Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS Université Lyon 1, Université de Lyon Villeurbanne France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2016 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
SESylvie Erpeldinger
Sylvie Erpeldinger
MRMichaela B. Rehman
Michaela B. Rehman
Christophe BerkhoutChristophe Berkhout
Christophe Berkhout
CPChristophe Pigache
Christophe Pigache
YZYves Zerbib
Yves Zerbib
RBRémy Boussageon
Rémy Boussageon
It is essential to anticipate and limit the social, economic and sanitary cost of type 2 diabetes (T2D), which is in constant progression worldwide. When blood glucose targets are not achieved with diet and lifestyle intervention, insulin is recommended whether or not the patient is already taking hypoglycaemic drugs. However, the benefit/risk balance of insulin remains controversial. Our aim was to determine the efficacy and safety of insulin vs. hypoglycaemic drugs or diet/placebo on clinically relevant endpoints. A systematic literature review (Pubmed, Embase, Cochrane Library) including all randomised clinical trials (RCT) analysing insulin vs. hypoglycaemic drugs or diet/placebo, published between 1950 and 2013, was performed. We included all RCTs reporting effects on all-cause mortality, cardiovascular mortality, death by cancer, cardiovascular morbidity, microvascular complications and hypoglycaemia in adults ≥ 18 years with T2D. Two authors independently assessed trial eligibility and extracted the data. Internal validity of studies was analyzed according to the Cochrane Risk of Bias tool. Risk ratios (RR) with 95 % confidence intervals (95 % CI) were calculated, using the fixed effect model in first approach. The I2 statistic assessed heterogeneity. In case of statistical heterogeneity, subgroup and sensitivity analyses then a random effect model were performed. The alpha threshold was 0.05. Primary outcomes were all-cause mortality and cardiovascular mortality. Secondary outcomes were non-fatal cardiovascular events, hypoglycaemic events, death from cancer, and macro- or microvascular complications. Twenty RCTs were included out of the 1632 initially identified studies. 18 599 patients were analysed: Insulin had no effect vs. hypoglycaemic drugs on all-cause mortality RR = 0.99 (95 % CI =0.92–1.06) and cardiovascular mortality RR = 0.99 (95 % CI =0.90–1.09), nor vs. diet/placebo RR = 0.92 (95 % CI = 0.80–1.07) and RR = 0.95 (95 % CI 0.77–1.18) respectively. No effect was found on secondary outcomes either. However, severe hypoglycaemia was more frequent with insulin compared to hypoglycaemic drugs RR = 1.70 (95 % CI = 1.51–1.91). There is no significant evidence of long term efficacy of insulin on any clinical outcome in T2D. However, there is a trend to clinically harmful adverse effects such as hypoglycaemia and weight gain. The only benefit could be limited to reducing short term hyperglycemia. This needs to be confirmed with further studies.

1 June 2015 in Diabetes & Metabolism
Verified
Journal Article
Closed access
TBT. Bejan-Angoulvant
T. Bejan-Angoulvant
CCC. Cornu
C. Cornu
PAP. Archambault
P. Archambault
BTB. Tudrej
B. Tudrej
PAP. Audier
P. Audier
RBR. Boussageon
R. Boussageon


1 June 2014 in Diabetes & Metabolism
Verified
Journal Article
Closed access
RBR. Boussageon
R. Boussageon
FGF. Gueyffier
F. Gueyffier
CCC. Cornu
C. Cornu

26 January 2017 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
RBRémy Boussageon
Rémy Boussageon
DPDenis Pouchain
Denis Pouchain
VRVincent Renard
Vincent Renard
To answer the questions that arise in relation to a patient’s clinical situation, medical decisions need to be made according to the principles of evidence-based medicine. At this time, the benefits and risks of glycaemic control in patients with type 2 diabetes require painstaking reconsideration.1 Even if chronic hyperglycaemia is a risk marker for some macro- and microvascular complications, that does not mean ipso facto that its reduction by one or several hypoglycaemic drugs is systematically beneficial to patients from a clinical point of view. The potential benefits derived from pharmacological glycaemic control can be counterbalanced by frequent and/or severe clinical adverse events. For example, numerous hypoglycaemic drugs have either not been made commercially available or have been withdrawn from the market in France because their risk–benefit ratio was deemed unfavourable: tolbutamide, phenformin, troglitazone, rosiglitazone, pioglitazone, benfluorex, rimonabant, muraglitazar, and aleglitazar. This was even though they pronouncedly reduced blood glucose level (on average from 0.5% to 2% of HbA1c). The main reason has had less to do with their clinical adverse events than with the lack of evidence of their clinical benefits. Had the efficacy of these drugs been demonstrated in terms of reduced morbidity and/or mortality, they would probably be on the market. To sum up, the scientific rationale for pharmacological treatment of patients with type 2 diabetes depends on the answers to two major questions: Several RCTs2–5 have evaluated the intensified glycaemic control strategies targeting an HbA1c level <7%, or even 6% …

8 January 2016 in BMJ
Verified
Journal Article
Closed access
PDF file
RBRémy Boussageon
Rémy Boussageon
FGFrançois Gueyffier
François Gueyffier
CCCatherine Cornu
Catherine Cornu
Rémy Boussageon and colleagues ask whether metformin is bringing practical benefit to patients and question the focus on surrogate measures